Company
Sydney, NSW
Every investor coverage indicates participated in a round Biotron raised.
Investors whose own portfolio pages list Biotron, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Significant Capital Ventures | its portfolio page ↗ |
Companies Biotron acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming Biotron. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney biotech Biotron reports lab results showing its hepatitis B drug candidate works against HBV and HDV, and will begin formal preclinical studies ahead of planned human trials in 2027.